PH&T S.p.A. is a privately owned Italian pharmaceutical company, founded in 1991 by senior managers with established experience in the pharmaceutical industry. The mission of PH&T is to develop ethical pharmaceuticals for niche therapeutical areas. PH&T portfolio includes not only generics but also new formulations of established out-of-patent drugs. PH&T is specialised in products which require high scientific and technological know-how in the development phase and medical promotion in the marketing phase. PH&T develops its own products and takes care of the related regulatory activities, while the marketing is entrusted to selected licensees and distributors. The supply of finished products to commercial partners is also part of PH&T commitment. PH&T is a growing company that has created a network of licensees and distributors in over 30 countries. PH&T concentrates its activities mainly in European countries, but in the last years it has grown also in the Middle and Far East and in Latin America.
Fuso Pharmaceutical Industries, Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceuticals and medical equipment. Along with its subsidiary, Fuso Pharmaceutical operates in two business segments. The Pharmaceuticals segment manufactures and sells pharmaceutical products, such as dialysates for artificial kidneys and injection solutions that include infusion solutions, as well as medical equipment and instruments. The Estate segment specializes in the leasing of real estate properties. The Company has one subsidiary. (Source: ARS)
Quigley Pharma understands what it takes to develop naturally derived pharmaceutical treatments for patients. Our research pipeline is diverse and includes antiviral and anti-inflammatory compounds, compounds to peripheral diabetic neuropathy and ocular herpes, and a compound shown to protect against the deleterious effects of ionizing radiation. Quigley Pharma welcomes strategic collaborations to supplement our product pipeline and to access complementary research, technology and development capabilities. We also seek to combine our strengths with those of others and to work collaboratively with partners to develop and commercialize naturally derived therapeutic products.
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical and Related Business segment is engaged in the development, manufacturing and sale of general pharmaceuticals and diagnostic drugs, including vitamin preparations, antipyretics and analgesics, cold and sinus medicine, digestive medicine, dermatologic preparations, test paper for glucose in urine and artificial teeth-related products. The Others segment is engaged in the leasing of real estate and the provision of logistics services. The Company has 11 subsidiaries and five associated companies.
Aspen Pharmacare markets a broad range of ethical products. These products of original research include a number of well established brands. Aspen Pharmacare's ethical business is a leader in the categories of female healthcare, tranquillisers and hypnotics and cardiovascular medicines. A number of co-marketing agreements have been concluded with multinational companies in terms of which Aspen Pharmacare distributes leading ethical products. Aspen Pharmacare is the leading supplier of generic medicines to the private and public sectors. This leadership position has been achieved by the broad range of quality pharmaceuticals the Group is able to supply at affordable prices. The introduction of new legislation in South Africa compelling generic substitution is expected to lead to an increase in the use of generic medicines. The generic product range is the core of the Group's public sector business which is serviced by the supply of state tenders, public sector hospitals and parastatal institutions. Over the counter (OTC) products are marketed exclusively through pharmacies. Increasing trends in self-medication make this a focus area. Aspen Pharmacare has built particular strength in the niche natural product sector. Another area of emphasis is in lifestyle intervention products which provide a greater sense of "well-being" for users. The fast moving consumer goods (FMCG) division markets a number of well-known and trusted household brands, which are found on the shelves of hypermarkets, supermarkets and cash and carry outlets. Aspen Pharmacare has entered into an agreement with Tibbett and Britten ("T&B") for the provision of its total distribution requirements. It is expected that the change to T&B, one of the world's leaders in supply chain management, will lead to an improvement in efficiencies and resultant cost savings. There are two pharmaceutical manufacturing plants within Aspen Pharmacare. Aspen Pharmacare Lennon, based in Port Elizabeth, is the Group's flagship factory and the heart of its generic business. It manufactures over 20 tons of finished product daily. Aspen Pharmacare East London is the site of the Group's important penicillin plant as well as a specialised aerosol facility. An oral contraceptive facility has also been commissioned at the East London site during the course of the past financial year. This facility manufactures to international quality standards. The new business development ("NBD") unit is responsible for identifying and sourcing new products for Aspen Pharmacare to bring to the market. The Group's pharmaceutical research laboratories ("PRL") are focused on the core activity of developing products which are the first-to-market in the domestic generic sector. PRL has experience in formulating most dosage forms. The Aspen Pharmacare regulatory division has developed sophisticated systems to constantly monitor and prioritise update requirements at an individual product level. These systems also allow for detailed business management of this function in an effort to move staff away from the typical reactive approach and to focus them on the key business needs. This is essential for achieving success given Aspen Pharmacare's large product range. The regulatory department works closely in co-operation with the South African Medicines Control Council ("MCC") in bringing new product registrations to the market.
Bioniche Life Sciences Inc. is a Canadian biopharmaceutical company engaged in the research, development, manufacturing and commercialization of human and animal health products and technologies worldwide. Headquartered in Belleville, Ontario, the Company has offices and manufacturing facilities in Canada, the United States, Europe, and Australia. The Company has three business units: Human Health, Animal Health, and Food Safety. The Human Health business unit is responsible for research, discovery and clinical development of human health products. The Animal Health business unit is responsible for the research, development, manufacturing and marketing of animal health products worldwide. The Food Safety business unit is responsible for research, development, manufacturing and marketing of biopharmaceutical animal health products to help prevent disease in humans and improve the safety of food and water supplies worldwide. (Source: ARS)
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products, which require a physician's prescription, as well as non-prescription pharmaceutical products sold over the counter. The Company's products in the United States consist of branded ethical drug specialties marketed directly or detailed to physicians by its sales forces, Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales. Forest Laboratories, Inc.'s products include Lexapro, the Company's selective serotonin reuptake inhibitor (SSRI) for the treatment of major depression and generalized anxiety disorder (GAD); Namenda, its N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe Alzheimer's disease; Bystolic, its novel beta-blocker for the treatment of hypertension, and Campral, for the maintenance of alcohol abstinence. (Source: 10-K)
CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in one segment, Human Health, which is divided into CSL Behring, and Other Human Health that includes CSL Biotherapies and CSL Bioplasma. CSL Behring provides plasma-derived and recombinant products. CSL Biotherapies manufactures and markets biological products for human use, and markets vaccines and other prescription pharmaceuticals for international partners. CSL Bioplasma manufactures plasma products to treat bleeding disorders (such as, hemophilia), to treat infections and autoimmune diseases, and to prevent hemolytic disease of the newborn. In July 2007, CSL Behring had been granted marketing approval from the United States Food and Drug Administration (FDA) for Privigen (Immune Globulin Intravenous (Human) 10% Liquid). In September 2007, FDA has approved the Company's influenza virus vaccine.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory